

Alzheimer Disease

New Drugs, Markets & Companies

by

Prof. K. K. Jain
MD, FRACS, FFPM
Jain PharmaBiotech
Basel, Switzerland

April 2018

A Jain PharmaBiotech Report

A U T H O R ' S B I O G R A P H Y

Professor K. K. Jain is a neurologist/neurosurgeon by training and has been working in the biotechnology/biopharmaceuticals industry for several years. He received graduate training in both Europe and US, held academic positions in several countries and is a Fellow of the Faculty of Pharmaceutical Medicine of the Royal College of Physicians of UK. Currently he is CEO and consultant at Jain PharmaBiotech. Prof. Jain's 474 publications including 28 books (5 as editor + 23 as author) and 50 special reports, which cover important areas in biotechnology, cell/gene therapies and biopharmaceuticals. Recent books relevant to the nervous system include "Handbook of Neuroprotection" (Springer, 2011) and "Applications of Biotechnology in Neurology" (Springer 2013). In addition to the above, he has edited "Applied Neurogenomics" (Springer 2015).

April 2018 (first edition in 2003)
Copyright © 2018 by

Jain PharmaBiotech
Bläsiring 7
CH-4057 Basel
Switzerland

Tel & Fax: +4161-6924461
Email: info@pharmabiotech.ch
Web site: http://pharmabiotech.ch/

All rights reserved. No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, or otherwise without the prior written permission of the Publisher. This report may not be lent, resold or otherwise traded in any manner without the consent of the Publisher. While all reasonable steps have been taken to ensure the accuracy of the information presented, the Publisher cannot accept responsibility for inadvertent errors or omissions.

TABLE OF CONTENTS

0. Executive Summary	17
1. Clinical Features, Epidemiology and Pathology	19
Introduction	19
Historical aspects	19
Clinical features of Alzheimer disease.....	20
Seven stages of Alzheimer disease.....	22
AD as a terminal illness	24
Detection of AD in the preclinical phase	24
Differentiation of AD from other dementias	24
Differentiation of AD from non-dementing disorders	26
Cerebral insufficiency and AD	26
Memory deficits and preclinical AD	26
Sleep disorders and AD.....	27
<i>Circadian rhythms and sleep in AD</i>	<i>27</i>
Mild cognitive impairment	28
Evolution of diagnostic criteria of AD	29
Revised criteria for the clinical diagnosis of AD	31
Epidemiology	32
Epidemiology of aging	32
Epidemiology of dementia	34
Epidemiology of AD.....	35
<i>Prevalence of AD according to age</i>	<i>35</i>
<i>Mortality in AD.....</i>	<i>35</i>
Pathophysiology of AD.....	35
Cerebral atrophy and neuronal loss	35
Neuritic plaques and neurofibrillary tangles	36
See-through 3D imaging of the AD brain.....	36
Sp proteins as markers of neuronal death in AD.....	37
Role of tau in the pathogenesis of AD	37
RNA-binding proteins and AD	39
Amyloid precursor protein	40
<i>APP intracellular domain</i>	<i>40</i>
<i>Relation of APP mutations to CNS disorders.....</i>	<i>40</i>
<i>Relation of APP to Aβ deposits and pathogenesis of AD</i>	<i>41</i>
<i>Role of neprilysin in Aβ degradation</i>	<i>42</i>
<i>Role of secretases in amyloid cascade</i>	<i>42</i>
<i>Role of exosomal proteins.....</i>	<i>44</i>
<i>Role of nicastrin.....</i>	<i>44</i>
Neurotoxicity of A β deposits.....	44
<i>Aβ production and clearance</i>	<i>45</i>
<i>Aβ-mediated synaptic and cognitive deficits</i>	<i>46</i>
<i>Dysfunction of TGF-β signaling accelerates Aβ deposition.....</i>	<i>47</i>
<i>Interaction of Aβ with neuron-specific Na$^{+}$/K$^{+}$-ATPase α3 subunit.....</i>	<i>47</i>
<i>Relation of Aβ deposits to synaptic activity.....</i>	<i>47</i>
<i>Role of TMP21 in presenilin complexes and Aβ formation</i>	<i>48</i>
<i>Role of Aβ dimers in the pathogenesis of AD.....</i>	<i>48</i>
<i>Role of dsDNA breaks in neurodegeneration due to Aβ.....</i>	<i>48</i>
<i>Structure–neurotoxicity relationships of Aβ oligomers.....</i>	<i>49</i>
<i>Sequence of events in neurotoxicity of Aβ.....</i>	<i>50</i>
Impairment of mitochondrial energy metabolism	51
<i>Aβ-binding alcohol dehydrogenase links AD to mitochondrial toxicity.....</i>	<i>51</i>
Neural thread protein	51
Loss of synaptic proteins.....	51
<i>AD and Down syndrome.....</i>	<i>52</i>
<i>Overlapping pathologies of AD and Parkinson disease.....</i>	<i>52</i>
<i>AD and age-related macular degeneration.....</i>	<i>53</i>
<i>Myelin hypothesis of AD.....</i>	<i>53</i>
<i>Blood-brain barrier in AD</i>	<i>53</i>
<i>Blood vessel damage in AD</i>	<i>54</i>
<i>Loss of serotonin 1A receptors in the brain.....</i>	<i>55</i>
Factors in pathogenesis of AD.....	55
<i>Astrocytes and AD.....</i>	<i>55</i>
<i>Axonal transport failure in AD.....</i>	<i>56</i>
<i>Cell-cycle hypothesis</i>	<i>56</i>
<i>Chronic heart failure link with AD.....</i>	<i>56</i>
<i>Creatine and AD</i>	<i>57</i>
<i>Disturbances in brain metabolism in early AD.....</i>	<i>57</i>

<i>Disturbances of interaction of nervous system proteins</i>	57
<i>Disturbance of lipid metabolism in the brain</i>	58
<i>DENN/MADD expression and enhanced pro-apoptotic signaling in AD</i>	58
<i>Dopamine and AD</i>	58
<i>Functioning role of genes in pathomechanism of AD</i>	58
<i>Gonadotrophins and AD</i>	59
<i>Glutamate transport dysfunction in AD</i>	59
<i>Herpes simplex virus type 1 and AD</i>	60
<i>Innate immune system and AD</i>	61
<i>Insulin, diabetes and AD</i>	61
<i>Mechanisms underlying cognitive deficits in AD</i>	62
<i>Microglia and AD</i>	63
<i>Monoamine oxidase and AD</i>	63
<i>Neuroinflammation and AD</i>	64
<i>Neurotransmitter deficits</i>	65
<i>Neurotrophic factors</i>	66
<i>NF-κB signaling and the pathogenesis of neurodegeneration</i>	66
<i>Nitric oxide and AD</i>	66
<i>Nogo receptor pathway</i>	69
<i>Oxidative stress and AD</i>	69
<i>Prostaglandins and AD</i>	71
<i>Quinolinic acid and AD</i>	71
<i>Retromer deficiency</i>	71
<i>Serotonin and AD</i>	72
Spread of neurodegeneration.....	72
<i>Synaptic failure in AD</i>	72
<i>Transmission of AD</i>	73
<i>Ubiquitin-proteasome system in pathogenesis of AD</i>	74
Risk factors in the etiology of AD.....	75
<i>Aging and developmental abnormalities of the cholinergic system</i>	75
<i>Cholesterol, dietary lipids, and Aβ</i>	76
<i>Epigenetic link between aging and AD</i>	77
<i>Exposure to magnetic fields</i>	77
<i>Family history of AD</i>	77
<i>Homocysteine and AD</i>	77
<i>Hypertension and AD</i>	78
<i>Level of education/type of job and risk of AD</i>	78
<i>Metals and AD</i>	79
<i>Obesity</i>	80
<i>Proneness to psychological distress and risk of AD</i>	81
<i>Reduced muscle strength</i>	81
<i>Sleep deprivation</i>	82
<i>Traumatic brain injury and AD</i>	82
<i>Vascular risk factors for AD</i>	83
<i>Vitamin B12 and folate</i>	85
AD versus non-dementing changes in the aging brain.....	85
AD and cognitive impairment with aging.....	85
Pathomechanism of memory impairment and AD.....	86
Concluding remarks on pathophysiology of AD.....	86
Genetics of AD	88
Familial AD.....	89
<i>Molecular genetics of familial AD</i>	89
<i>Presenilins and calcium channel pathogenesis of familial AD</i>	90
<i>Presenilin-1 mutations and familial AD</i>	90
Late onset AD.....	91
Genomics of AD	91
Introduction to genomics.....	91
Genes associated with Alzheimer disease.....	91
<i>AlzGene database</i>	93
<i>ApoE gene</i>	93
<i>ApoE genotype and nitric oxide</i>	94
<i>ApoE genotype modulates AD phenotype</i>	95
<i>APOE genotype and age-related myelin breakdown</i>	95
<i>ApoE receptor interaction with NMDA receptor</i>	96
<i>ApoE and ApoER2</i>	96
<i>ApoE receptor LR11 as regulator of Aβ</i>	97
<i>Arctic mutation</i>	97
<i>BCHE gene</i>	97
<i>BRCA1 and AD</i>	97
<i>CALHM1 polymorphism and AD</i>	98
<i>CLU, CRI and PICALM</i>	98

<i>CYP46 and risk for AD</i>	98
<i>DAPK1 gene variants and AD</i>	99
Genetic variants associated with early-onset AD	99
Genetic variants associated with late-onset AD	99
<i>ApoE polymorphisms associated with LOAD</i>	99
<i>Copy number variation (CNV) in LOAD</i>	100
<i>LRRTM3 as a candidate gene for AD</i>	100
<i>MTHFD1L gene variant associated with AD</i>	100
<i>Mutation in APP gene with protective effect against AD</i>	101
<i>OGG1 mutations associated with AD</i>	101
<i>SORL1 gene in AD</i>	101
<i>TOMM40 gene and risk of AD</i>	102
<i>TREM2 variants in AD</i>	102
International Genomics of Alzheimer's Project	102
Sequencing in Alzheimer disease	103
Molecular neuropathology	105
Role of microRNAs in AD	105
DNA methylation in AD	106
AD as a polygenic disorder	107
Proteomics of AD	107
Introduction	107
Application of proteomic technologies to study AD.....	107
Protein misfolding in AD.....	110
Common denominators of AD and prion diseases.....	110

2. Diagnostic Procedures for Alzheimer Disease 113

Importance of the diagnosis of Alzheimer disease	113
Methods of diagnosis of AD	113
Self-administered olfactory test	114
Neuropsychological testing.....	114
Assessment and evaluation	115
<i>7-minute screen</i>	115
<i>15-point risk index</i>	116
<i>Activities of Daily Living</i>	116
<i>Alzheimer Disease Cooperative Study</i>	116
<i>CDR-SOB score</i>	116
<i>Clinician's Interview-Based Impression of Change</i>	117
<i>DETECT™ System</i>	117
<i>Measurement of aggregation in anterior segment of the eye</i>	117
<i>Resource Utilization in Dementia Battery</i>	117
<i>SymptomGuide™</i>	117
Electrophysiology	118
<i>Quantitative EEG for investigation of early AD</i>	118
<i>EEG-based bispectral index</i>	118
<i>Event-related potentials</i>	118
<i>Correlation of electrical activity of the brain with cognition</i>	119
Early detection of cataract associated with AD	119
Retinal imaging to detect A β deposits	119
Laboratory methods for diagnosis of AD.....	120
Monitoring of synthesis and clearance rates of A β in the CSF	121
Molecular diagnostics for AD.....	121
<i>Genetic tests for AD</i>	122
<i>ApoE genotyping</i>	123
<i>Gene expression patterns in AD</i>	123
<i>Monoclonal antibody-based in vitro diagnosis of AD from brain tissues</i>	123
<i>Multi-tissue RNA signature of aging as diagnostic for AD</i>	123
Biomarkers of AD.....	124
The ideal biomarker for AD.....	126
CSF biomarkers of AD	126
<i>CSF sulfatide as a biomarker for AD</i>	126
<i>Glycerophosphocholine as CSF biomarker in AD</i>	127
<i>Protein biomarkers of AD in CSF</i>	127
<i>Tau proteins in CSF</i>	129
<i>Tests for the detection of Aβ in CSF</i>	129
<i>Tests combining CSF tau and Aβ</i>	130
<i>Concluding remarks about CSF biomarkers of AD</i>	130
Urine tests for AD	131
Blood tests for AD	131
<i>Blood Aβ level as biomarker of AD</i>	131
<i>Blood test for AD based on heme oxygenase-1</i>	132
<i>Blood test for AD based on RNA hybridization</i>	132

<i>GSK-3 elevation in white blood cells</i>	133
<i>Lipid biomarkers for preclinical detection of AD</i>	133
<i>Lymphocyte Proliferation Test</i>	133
<i>Metabolomic biomarker profiling</i>	133
<i>MGAT3 as biomarker for prognosis of AD</i>	134
<i>MicroRNA-based test for AD</i>	134
<i>Protein kinase C in red blood cells</i>	134
<i>Sphingolipids</i>	135
<i>Tests based on protein biomarkers in blood</i>	135
Skin test for early detection of AD	135
Saliva-based tests for AD	136
<i>Saliva Aβ42 level as a biomarker of AD</i>	136
Smell identification test	136
Nanotechnology to measure A β -derived diffusible ligands	136
Simultaneous measurement of several biomarkers for AD	137
Nutritional biomarkers in plasma of AD patients	137
Plasma biomarkers of drug response in AD	138
A serum protein-based algorithm for the detection of AD	138
Concluding remarks about biomarkers for AD	138
Imaging in AD	139
Computed tomography	139
Magnetic resonance imaging	139
<i>Arterial spin labeling with MRI</i>	140
<i>Magnetic resonance microscopy</i>	140
<i>Magnetic resonance spectroscopy</i>	141
Single photon emission computed tomography and modifications	141
Positron emission tomography	142
In vivo imaging of A β deposits by PET	144
<i>Pittsburgh compound B and PET</i>	144
<i>Florbetapir-PET</i>	145
<i>Florbetaben-PET</i>	146
<i>Flutemetamol-PET</i>	146
<i>Future prospects of the PET imaging in AD</i>	147
In vivo detection of A β plaques by MRI	147
Imaging agents for A β and neurofibrillary tangles	147
Hyperspectral Raman imaging of neuritic plaques in AD	148
Targeting of a chemokine receptor as biomarker for brain imaging	149
Radiiodinated cloquinol as a biomarker for A β	149
In vivo imaging of tau by PET	149
Imaging neuroinflammation in AD by PET	150
Preclinical diagnosis of AD	150
<i>Correlation of imaging with CSF biomarkers for early detection of AD</i>	151
Meta-analysis of literature on imaging in AD	151
Alzheimer Disease Neuroimaging Initiative	151
Computer aided diagnosis systems for AD based on imaging data	152
Concluding remarks on imaging for diagnosis of AD	153
Diagnosis of MCI and prediction of AD	153
Diagnosis of MCI	153
<i>Computer-Administered Neuropsychological screen for MCI</i>	153
<i>Infrared eye-tracking technology to detect MCI</i>	154
<i>MRI for detection of MCI</i>	154
<i>PET for detection of MCI</i>	154
<i>Role of APOE genotype in early MCI</i>	155
Presymptomatic detection of AD	155
<i>Biomarker changes in autosomal dominantly inherited AD</i>	156
<i>Blood test for preclinical diagnosis of AD</i>	156
<i>Gait analysis during cognitive tasks</i>	156
PredictAD project	157
Prediction of AD in patients with MCI	157
<i>Biochemical biomarkers in CSF for prediction of AD</i>	157
<i>Clinical and biochemical biomarkers for profiling prodromal AD</i>	157
<i>Combination of MMSE and a memory test for prediction of AD</i>	158
<i>Plasma protein biomarkers of conversion of MCI to AD</i>	158
<i>Structural MRI biomarkers for prediction of AD</i>	158
<i>Magnetoencephalography for detection of MCI and AD</i>	158
<i>MRI-based index to measure the severity of AD in MCI</i>	159
<i>Concluding remarks about prediction of AD in MCI</i>	159
Criteria for diagnosis of AD	160
Role of biomarkers in diagnosis of AD dementia	161
Ethical aspects of diagnostics for AD	162
Genetic testing for AD	162

Ethical issues of brain imaging in AD	163
Monitoring of treatment of AD	163
<i>Monitoring treatment of mixed AD and vascular dementia</i>	163
Companies involved in diagnosis of AD	163

3. Management of Alzheimer Disease	165
Introduction	165
Cholinergic approaches	165
Mechanism of action of cholinesterase inhibitors	166
Choline and lecithin	167
Donepezil	168
Rivastigmine	169
Galantamine	170
Duration of treatment with ChE inhibitors	171
Comparative studies of ChE inhibitors	171
Donepezil versus rivastigmine	172
Donepezil versus galantamine	172
Combination of cholinesterase inhibitors and a cholinergic precursor	172
An assessment and future prospects of anticholinergic therapies	173
Neuroprotection in Alzheimer's disease	174
Memantine	174
<i>Pharmacology of memantine</i>	174
<i>Clinical trials of memantine</i>	175
<i>Combination of memantine with ChE inhibitors</i>	177
Monoamine oxidase inhibitors	178
<i>Selegiline</i>	178
Synaptoprotection in AD	178
Drugs for noncognitive symptoms in AD	179
Antidepressants	179
Antipsychotics	179
ChE inhibitors for behavioral and psychological disorders in AD	180
Concluding remarks and other drugs for agitation in AD	180
Sensory stimulation	181
Non-pharmacological treatments of AD	181
Cerebrospinal fluid shunting	181
Deep brain stimulation	182
Exposure of the brain to electromagnetic fields for treatment of AD	183
<i>Application of electrical fields for improvement of cerebral function</i>	183
<i>High-frequency electromagnetic field treatment of AD</i>	183
<i>Transcranial magnetic stimulation</i>	184
Mental training for management of memory loss in AD	184
Microchip-based hippocampal prosthesis for AD	184
Omental transposition	185
Photo-induced inhibition of A β accumulation in AD	185
Scanning ultrasound for removal of A β	185
Vagal nerve stimulation	186
Nutritional therapies for AD	186
Axona	186
Cocktail of dietary supplements for AD	186
Docosahexaenoic acid	187
Magnesium	188
Nicotinamide for the treatment of AD	189
Omega-3 fatty acids	189
Preventing decline of mental function with aging and dementia	190
Prevention of Alzheimer disease	191
Mental training	192
Physical exercise	192
Higher level of conscientiousness and decreased risk of AD	193
Nutritional factors in prevention of AD and MCI	193
<i>Black and green teas</i>	194
<i>Caffeine</i>	194
<i>Caloric restriction</i>	195
<i>Cinnamon</i>	195
<i>Cocoa flavonol consumption</i>	195
<i>Grapes and red wine</i>	195
<i>Vitamin D and docosahexaenoic acid</i>	197
Drugs to prevent Alzheimer disease	197
Preimplantation genetic diagnosis of inherited Alzheimer disease	197
Presymptomatic detection of AD	197
Management of mild cognitive impairment	198
Slowing the progression of MCI to AD	198

Management of Down syndrome.....	199
Guidelines for use of anti-dementia drugs in clinical practice.....	200
Donepezil and/or memantine.....	200
General care of the Alzheimer disease patients	201
Strategies for the management of Alzheimer disease	201
4. Research in Alzheimer Disease	203
Introduction	203
Animal models of Alzheimer disease.....	203
Lesional models.....	203
<i>Cerebroventricular injection of Aβ in rats</i>	<i>203</i>
<i>Lentiviral vector-based models of amyloid pathology</i>	<i>204</i>
<i>AAV-mediated gene transfer to increase hippocampal Aβ.....</i>	<i>204</i>
Transgenic mouse models.....	204
<i>Quantitative assessment of amyloid load in transgenic models.....</i>	<i>205</i>
<i>In vivo magnetic resonance microimaging in transgenic models of AD</i>	<i>206</i>
<i>Transgenic model of AD with suppression of Aβ production.....</i>	<i>206</i>
<i>Transgenic AD11 anti-NGF mice.....</i>	<i>206</i>
<i>Genetically altered mice with deficiency of vesicular ACh transporter.....</i>	<i>207</i>
<i>Limitations of mouse models of Alzheimer disease</i>	<i>207</i>
<i>Improved mouse models of AD expressing human genes</i>	<i>208</i>
Cholesterol-fed rabbits as models for AD.....	208
Canine dementia as model for AD	208
Zebrafish model for AD	209
Transgenic invertebrate models of Alzheimer disease	210
<i>Drosophila model of AD</i>	<i>210</i>
<i>Caenorhabditis elegans Alzheimer disease model</i>	<i>210</i>
Correlation of studies in animal models and human clinical trials.....	211
Cell systems for AD research	212
In vitro neuronal cell Lines.....	212
Single-gene expression system for use in cell culture	212
Stem cells for testing efficacy of AD drugs	212
Transgenic cells	213
In silico models	213
Estimation of progression rates of Alzheimer disease.....	214
Clinical trial methods in Alzheimer disease.....	214
Molecular imaging as a guide to drug development	215
Use of MRI and PET in clinical trials	215
Cognitive-function assessment in clinical trials.....	216
Clinical trials in mild cognitive impairment.....	216
Research in AD as a basis for future therapies.....	217
Use of microarrays for studying pathogenesis of AD	217
Computational brain mapping in AD	217
Study of neurogenesis in AD	217
Study of 3D structure of A β	217
Solid-state NMR to study precursors of A β	218
Research in Alzheimer disease at academic centers	218
Role of NIH in AD research.....	218
NIH Clinical Trials Database for AD.....	218
Alzheimer Research Consortium.....	218
The National Institute on Aging and AD research	219
5. Drug Discovery & Development for Alzheimer Disease	221
Introduction	221
Categories of drugs in development for AD.....	221
Memory-enhancing drugs	223
Enhancing memory by drugs that block eIF2 α phosphorylation	223
Drugs based on cholinergic approaches.....	223
AP2238.....	224
Butyrylcholinesterase inhibitors	224
Donepezil-tacrine hybrids.....	224
Drugs modulating gamma-aminobutyric acid receptors.....	225
Ganstigmina.....	225
Methanesulfonyl fluoride	225
Muscarinic receptor modulators	226
<i>Muscarinic M1 agonists.....</i>	<i>226</i>
<i>Muscarinic M2 antagonists.....</i>	<i>227</i>
Nicotine and nicotinic receptor modulators	227
<i>Nicotine.....</i>	<i>227</i>
<i>Nicotinic receptor modulators</i>	<i>228</i>
<i>GTS21</i>	<i>230</i>

<i>Ispronicline</i>	231
<i>JWB1-84-1</i>	231
Neuropeptide/neurotransmitters	231
Somatostatin release enhancers	231
Glutamate receptor modulators	232
Physiology and pharmacology of glutamate receptors	232
NMDA receptor ion channel complex	232
Metabotropic glutamate receptors	233
Glutamate receptor modulators as potential therapeutics for AD	234
<i>N20C</i>	235
<i>AMPA modulators</i>	235
Glutamate release inhibitors	236
<i>INI-0602</i>	236
Drugs affecting multiple neurotransmitters	236
Ensaculin	236
RS-1259	236
Lecozotan	236
Vaccines for AD	237
Active immunization with A β	237
<i>AN-1792 vaccine</i>	237
<i>Complications in clinical trials with AN-1792</i>	238
<i>Effects of Aβ vaccine on the brain</i>	238
Strategies to avoid undesirable effect of A β vaccination	239
Passive immunization in AD	240
<i>Passive immunization with MAbs</i>	240
<i>Clinical trials of MAbs in AD</i>	241
<i>Delivery of the passive antibody directly to the brain</i>	242
<i>Systemic injection of MAbs to treat AD</i>	243
Combination of A β immunotherapy and CD40-CD40L blockade	243
Shaping the immune responses elicited against A β	243
Delivery of AD vaccines	244
<i>Gene vaccination</i>	244
<i>Modified Aβ nasal vaccine</i>	245
<i>Transdermal Aβ vaccination</i>	245
Other vaccines for AD	245
<i>Nasal vaccination with Proteosome™ adjuvant</i>	246
<i>T cell vaccination with glatiramer acetate adjuvant</i>	246
Early start of immunotherapy for clearing A β plaques	246
Reversal of cholinergic dysfunction by anti-A β antibody	246
Immune modulation via Toll-like receptors to reduce A β	247
Mechanisms by which A β antibodies reduce amyloid accumulation in the brain	247
Perspectives on vaccines for AD	248
Companies involved in AD vaccines	250
Inhibition of amyloid precursor protein aggregation	250
Secretase modulators	250
<i>Neuroprotection by α-secretase cleaved APP</i>	251
<i>Inhibitors of β-secretase</i>	252
<i>Inhibitors of γ-secretase</i>	253
Amyloid-derived diffusible ligands	254
GABA receptor modulation by etazolate and APP processing	255
Depletion of serum amyloid P	255
Drugs that inhibit the formation of Aβ	255
22R-hydroxycholesterol	256
Acylaminopyrazole	256
Cadmium telluride nanoparticles prevent A β fibril formation	256
Cannabinoids	256
Chelation therapy for AD	257
<i>Clioquinol and PBT2</i>	257
<i>Copper chelation by FKBP52</i>	259
<i>Zinc chelation from amyloid plaques</i>	260
<i>Next generation multifunctional chelating agents for AD</i>	260
Heparin and its derivatives	260
<i>A reassessment of the role of heparin in AD</i>	260
<i>Enoxaparin</i>	261
<i>Heparan sulfate</i>	261
Imatinib mesylate	261
Laminin	262
Masitinib	262
NSAIDs	262
<i>Flurbiprofen analogs with Aβ42-lowering action</i>	263
<i>Nitric oxide-donating NSAIDs</i>	264

<i>In vivo demonstration of the effects of NSAIDs on brain in AD</i>	264
Paclitaxel	265
Phenserine	265
<i>Tolserine</i>	266
Platinum-based inhibitors of A β	266
Retro-inverso peptide inhibitor	266
Scyllo-cyclohexanehexol	266
Selective serotonin reuptake inhibitor	267
Small molecule drug discovery for inhibiting A β aggregation	267
Trojan-horse approach to prevent build-up of A β aggregates	267
Ubiquitin C-terminal hydrolase L1	268
Drugs to prevent the formation of NFTs	268
Tau suppression	269
Anthraquinones	269
Anti-tau antibodies	269
Tau aggregation inhibitor rember™	269
LMTX®	270
Microtubule stabilizers	270
ApoE4 as a therapeutic target in AD	270
Strategies to prevent deposits and enhance clearance of Aβ	271
4,5-dianilinophthalimide for disruption of A β ₁₋₄₂ fibrils	271
ABCA1 overexpression to lower amyloid deposits	272
ANAVEX 2-73	272
Beta-sheet breakers	273
Bexarotene	273
Blocking ApoE/A β interaction to reduce A β plaques	274
CD33 inhibitors	274
Clearance of A β across the blood-brain barrier	274
Enhanced PKC ϵ activity promotes clearance of A β	275
Galantamine-induced A β clearance	275
Hemopheresis	275
Inhibitors of A β dehydrogenase	275
Intravenous immune globulin	276
Monoclonal antibodies for removal of A β	277
<i>Crenezumab</i>	277
<i>Gantenerumab</i>	277
<i>Solanezumab</i>	278
Nanotechnology for removal of A β deposits	278
Role of matrix metalloproteinases in clearance of A β	278
Serum amyloid P component depletion	279
Small molecule DAPH for clearance of amyloid	279
Companies developing Aβ-directed therapeutics for AD	279
Nootropics	280
Acetyl-L-carnitine	281
Cerebrolysin	281
Ergot derivatives	282
<i>Lisuride</i>	282
<i>Dihydroergocryptine</i>	282
Neuroprotective effect drugs not primarily developed for AD	282
Antiepileptic drugs	283
<i>Lamotrigine</i>	283
<i>Levetiracetam</i>	283
Antiinflammatory and antimicrobial drugs	284
<i>Dapsone</i>	284
<i>Antimicrobial drugs against C. pneumoniae</i>	284
<i>PPAR-gamma agonists</i>	284
Antidiabetic drugs	285
<i>Insulin</i>	285
<i>Metformin</i>	285
<i>Rosiglitazone</i>	286
<i>Pioglitazone</i>	286
Antihypertensive drugs	287
<i>Angiotensin-converting enzyme inhibitors</i>	287
<i>Angiotensin receptor blockers</i>	287
Bexarotene	287
Dimebon	287
Drugs acting on estrogen receptors	288
<i>Estrogen</i>	289
<i>Raloxifene</i>	289
Inhibitors of neuroinflammation	290
<i>Ceramide</i>	290

<i>CSP-1103</i>	290
<i>Cyclophosphamide</i>	290
<i>Etanercept</i>	291
<i>Fingolimod</i>	291
<i>Interferon beta-1a</i>	291
<i>MW01-5-188WH</i>	292
Neurosteroids	292
<i>Pregnenolone sulfate</i>	292
<i>Dehydroepiandrosterone</i>	293
Lithium	293
MAO-B inhibitors	293
<i>Ladostigil tartrate</i>	294
Momoquin	294
Methylene blue	295
Nilotinib	295
Nimodipine	295
Rapamycin	296
Saracatinib	296
Statins	296
Testosterone	297
Valproic acid	298
Future prospects of neuroprotection in AD	298
<i>Targeting Cdk5 pathway</i>	299
Antioxidants	299
Colostrinin	300
Curcumin	300
Dehydroascorbic acid	301
Reservatrol	301
Synthetic catalytic scavengers	302
Vitamins	302
Vitamin E as antioxidant	302
Vitamin B for lowering homocysteine	302
Folic acid	303
Aminopyridazines	303
Nanobody-based drugs for AD	304
Nitric oxide based therapeutics for AD	304
Nitric oxide mimetics	304
iNOS inhibitors for AD	304
Novel drugs for AD from natural resources	305
Berberine chloride	306
<i>Centella asiatica</i>	306
<i>Ginko biloba</i>	306
Huperzine-A	307
Hyperforin	308
<i>Melissa officinalis</i>	308
Nostocarboline derived from cyanobacteria	308
<i>Salvia</i>	309
<i>Securinega suffruticosa</i>	309
<i>Withania somnifera</i>	309
ZT-1	309
Cholesterol and AD	310
ACAT inhibitors	311
Role of gene for cholesterol ester transfer protein	312
Cholesterol 24S-hydroxylase as a drug target for AD	312
Selectively increase of ApoA-I production	312
Neurotrophic factors	312
Brain derived neurotrophic factor	313
Insulin-like growth factor-1	313
Nerve growth factor	314
Neotrofin (AIT-082)	314
Limitations of the use of NTFs for AD	315
Role of serotonin modulators in AD	315
Xaliproden	315
5-HT _{1A} receptor antagonists	315
5-HT ₆ antagonists	316
5-HT ₄ receptor agonists	316
<i>PRX-03140</i>	317
<i>Donecopride</i>	317
Restoration of factors deficient in the aging brain	317
Reversal of cognitive impairment in aging by activation of creb protein	317
Reversal of cognitive impairment in aging by GDF11 protein	318

Restoration of repressor element 1-silencing transcription factor.....	318
Cell therapy for AD.....	318
Stem cell transplantation for AD	319
<i>Potential benefits of grafting NSCs in AD.....</i>	<i>319</i>
<i>NSCs improve cognition in AD via BDNF.....</i>	<i>319</i>
<i>Drugs for enhancing neuronal differentiation of implanted NSCs</i>	<i>320</i>
Choroid plexus epithelial cells for AD	320
Implantation of encapsulated cells for delivering NGF	320
Gene therapy for AD	320
ApoE gene therapy.....	321
<i>APPsa gene transfer for rescuing synaptic failure in AD.....</i>	<i>321</i>
FGF2 gene transfer in AD	321
Humanin gene therapy	322
Nepriylisin gene therapy	322
NGF gene therapy	322
Targeting plasminogen activator inhibitor type-1 gene.....	324
Antisense approaches to AD	324
Antisense PNA in AD.....	324
Antisense tau in AD.....	324
RNAi approaches to AD	325
Combined therapeutic approaches to AD	326
Drug delivery for Alzheimer disease	326
Delivery of biologicals across the BBB.....	327
Delivery of thyrotropin-releasing hormone analogs by molecular packaging.....	327
Nanoparticle-based drug delivery for Alzheimer's disease.....	328
Transdermal drug delivery in Alzheimer's disease.....	328
<i>Transdermal rivastigmine.....</i>	<i>329</i>
Intranasal delivery of therapeutics for AD	329
<i>Intranasal delivery of tacrine.....</i>	<i>329</i>
<i>Intranasal delivery of nerve growth factor to the brain.....</i>	<i>329</i>
Circadian rhythms and timing of cholinesterase inhibitor therapy	330
Clinical trials for AD	330
Drugs for AD that were discontinued in clinical trials	336
Concluding remarks on clinical trials of AD	339
Drug discovery for AD.....	340
Drugs acting on signaling pathways	340
<i>Activation of GTPase signaling by Cytotoxic Necrotizing Factor 1</i>	<i>340</i>
<i>Drugs to reverse inhibition of the PKA/CREB pathway in AD</i>	<i>340</i>
<i>Inhibition of the CD40 signaling pathway</i>	<i>341</i>
<i>JNK pathway as a target.....</i>	<i>342</i>
<i>Mitogen-activated protein kinase pathway as target</i>	<i>342</i>
<i>Protein kinase C activators</i>	<i>342</i>
Electrophysiological detection of drug target for neuroprotection in early AD	343
Genomics-based drug discovery.....	343
High through screening for AD drug candidates	343
New chemical entities for AD by combining galantamine and memantine	344
Novel rivastigmine-hydroxycinnamic acid hybrids for AD.....	344
Novels targets/receptors for AD drug discovery	344
<i>Activation of cerebral Rho GTPases</i>	<i>344</i>
<i>Activators of insulin-degrading enzyme.....</i>	<i>345</i>
<i>Blockade of TGF-β-Smad2/3 signaling in peripheral macrophages</i>	<i>345</i>
<i>Calcium channel blockers.....</i>	<i>345</i>
<i>Calpain inhibitors.....</i>	<i>346</i>
<i>Casein kinase 1</i>	<i>346</i>
<i>Cyclin-dependent kinase-5.....</i>	<i>346</i>
<i>Drugs against arginine deprivation and immune suppression in AD</i>	<i>347</i>
<i>Heat shock protein 90 inhibitors.....</i>	<i>347</i>
<i>Histone deacetylase inhibitors</i>	<i>348</i>
<i>Inhibition of PDK1 to slow progression of both AD and prion disease</i>	<i>348</i>
<i>Melatonin.....</i>	<i>348</i>
<i>Neurotrophic compound J147</i>	<i>349</i>
<i>NF-κB inhibitors.....</i>	<i>349</i>
<i>Kinases and phosphatases as targets for AD therapeutics</i>	<i>349</i>
<i>Neutral sphingomyelinase inhibitors</i>	<i>350</i>
<i>Phosphodiesterase inhibitors</i>	<i>350</i>
<i>Pin 1 as a target in AD.....</i>	<i>351</i>
<i>Protein phosphatase 5 as a neuroprotective in AD.....</i>	<i>351</i>
<i>Single drugs for multiple targets in AD</i>	<i>352</i>
<i>Src homology-containing protein-1 inhibitors.....</i>	<i>352</i>
<i>Targeting GABAergic system</i>	<i>352</i>
<i>TSPO ligands.....</i>	<i>352</i>

Proteomics and drug discovery for AD	353
Small molecule compounds binding to neurotrophin receptor p75NTR.....	354
<i>Targeting Vav in tyrosine kinase signaling pathway</i>	355
<i>LM11A-31 as p75NTR ligand</i>	355
Pharmacogenomics of Alzheimer disease	356
Biomarkers and companion diagnostics for AD.....	356
Personalized therapy of AD	356
Genotyping and AD therapeutics.....	357
Regulatory aspects of drug development for AD	358
EMA guidelines for drug development for AD	358
FDA guidelines for drug development for AD.....	359
Concluding remarks and future of AD research.....	360
Future for AD therapeutics	360
6. Markets & Finances of AD Care	363
Introduction	363
Pharmacoeconomics of treatment of AD	363
Quality of Life in relation to economics of AD.....	363
Costs associated with Alzheimer disease	363
Pharmacoeconomics of donepezil	364
Pharmacoeconomics studies using rivastigmine	364
Pharmacoeconomics studies using galantamine	365
Pharmacoeconomics studies using memantine.....	365
Patterns of AD care in major markets	365
Care of AD patients in the US	366
<i>Cost of care</i>	366
<i>Medicare and AD</i>	367
<i>Patterns of practice in AD care</i>	368
<i>Opinions of physicians' organizations on drugs for dementia</i>	368
Care of AD patients in the UK	369
<i>Cost of care</i>	369
<i>Patterns of practice in AD care</i>	369
<i>NICE recommendations to NHS</i>	370
Care of AD patients in Germany.....	371
Care of AD patients in France	372
Care of AD patients in Italy	372
Care of AD patients in Spain.....	372
Care of AD patients in Japan	373
Markets for AD diagnostics	373
Markets for AD therapeutics	373
Geographical markets for AD.....	373
Markets for currently approved drugs for AD	374
Markets for generic AD drugs	375
Statins.....	375
Future growth of AD market.....	375
Limitations of AD drug development by the biotechnology industry	376
Unmet needs in the management of AD	377
Drivers of AD markets.....	378
Increase of the aged populations	378
Increase in the number of approved drugs for AD	378
Limitations of the current therapies.....	379
Improvements in diagnosis	379
Increasing awareness of the disease	379
7. Companies	381
Introduction	381
Profiles of companies.....	381
Collaborations.....	505
8. References.....	509

Tables

Table 1-1: Historical landmarks relevant to Alzheimer disease.....	19
Table 1-2: Clinical features of Alzheimer disease	20
Table 1-3: Non-Alzheimer dementias	25
Table 1-4: A guide to evaluation for MCI due to AD.....	29
Table 1-5: NINCDS-ADRDA Criteria for diagnosis of Alzheimer disease	30
Table 1-6: 2011 Revised criteria for diagnosis of dementia due to Alzheimer Disease	31
Table 1-7: Relation of mutations in amyloid precursor protein to CNS disorders.....	41

Table 1-8: Risk factors for Alzheimer's disease	75
Table 1-9: Genes linked to AD	92
Table 1-10: Abnormalities of expression of brain proteins in Down's syndrome and AD.....	108
Table 2-1: Classification of methods of diagnosis of Alzheimer disease	113
Table 2-2: Neuropsychological test batteries and scales for Alzheimer's disease	114
Table 2-3: Available molecular diagnostic tests for Alzheimer disease.....	122
Table 2-4: Biomarkers of AD in blood and CSF	124
Table 2-5: Characteristics of an ideal biomarker for Alzheimer disease	126
Table 2-6: Role of biomarkers in diagnosis of AD dementia	161
Table 2-7: Companies involved in the diagnosis/monitoring of Alzheimer disease	164
Table 3-1: Classification of treatments for Alzheimer disease	165
Table 3-2: Cholinergic approaches used in the treatment of Alzheimer disease.....	166
Table 3-3: Categories of neuroprotective agents for Alzheimer disease.....	174
Table 3-4: Strategies for prevention of Alzheimer disease.....	191
Table 3-5: Guidelines for the treatment of dementia	200
Table 4-1: Transgenic mouse models of Alzheimer disease	204
Table 4-2: Correlation of studies in animal models with human clinical trials	211
Table 5-1: Classification of therapies in development for Alzheimer disease	221
Table 5-2: Drugs for AD targeting nACh receptors	230
Table 5-3: Ionotropic glutamate receptors	232
Table 5-4: Classification of mGluRs.....	232
Table 5-5: Glutamate receptor modulators as potential therapeutic agents in AD.....	234
Table 5-6: Companies involved in developing vaccines for AD	250
Table 5-7: Preclinical studies of secretase modulators	251
Table 5-8: Secretase modulators in clinical trials	251
Table 5-9: Companies developing A β -directed therapeutics for AD.....	279
Table 5-10: Innovative neuroprotective approaches for Alzheimer disease	282
Table 5-11: Herbal therapies for AD	305
Table 5-12: Novel drug delivery methods for Alzheimer disease therapies.....	326
Table 5-13: Clinical trials in Alzheimer disease	331
Table 5-14: Discontinued, failed or inconclusive clinical trials of Alzheimer disease	336
Table 6-1: Direct and indirect costs associated with Alzheimer disease	366
Table 6-2: Prevalence of AD in major markets 2017-2027	374
Table 6-3: AD market values from 2017-2027 in major world markets	374
Table 6-4: Markets for currently approved AD drugs 2017-2027	375
Table 6-5: Potential markets for drugs in development 2017-2027	376
Table 6-6: Limitations of AD drug development by the biotechnology industry.....	376
Table 6-7: Factors that drive AD markets	378
Table 7-1: Major players in Alzheimer's disease therapeutics.....	381
Table 7-2: Collaborations relevant to Alzheimer disease	505

Figures

Figure 1-1: Percentages of world population of people over the age of 65 according to more developed and less developed portions – 2000 to 2050.....	32
Figure 1-2: Correlation between aging and AD in the US from 2000 to 2020	33
Figure 1-3: Prevalence of different types of dementia.....	34
Figure 1-4: Structure of tau in a brain with AD	38
Figure 1-5: A β deposits in the brain	45
Figure 1-6: Mechanisms of A β clearance.....	46
Figure 1-7: Pathways for A β -induced nerve cell death	50
Figure 1-8: Insulin signaling in Alzheimer disease and diabetes	62
Figure 1-9: Nitric oxide neurotoxicity and neuroprotection in relation to Alzheimer disease	68
Figure 1-10: Oxidative stress and Alzheimer disease	70
Figure 1-11: Role of proteasome inhibition in A β generation and neurodegeneration	74
Figure 1-12: Cholesterol-related pathways to AD	76
Figure 1-13: Pathomechanism of AD	88
Figure 3-1: Metabolism of acetylcholine.....	167
Figure 3-2: Neuroprotective effective of galantamine in AD.....	171
Figure 3-3: Strategies for the management of Alzheimer disease.....	201
Figure 5-1: Activation of α 7 nicotinic acetylcholine receptors.....	229
Figure 5-2: NMDA receptor ion channel complex.....	233
Figure 5-3: Neurotoxicity due to misfolding of A β 1-42	272
Figure 5-4: Interactions of players in clinical trials of Alzheimer disease in the USA.....	331
Figure 5-5: Role of proteomics in drug discovery/development for Alzheimer disease.....	354
Figure 5-6: FDA industry interaction during drug development for AD	359
Figure 5-7: FDA's accelerated approval pathway in early Alzheimer disease	361
Figure 6-1: Unmet needs in the management of Alzheimer disease.....	377